Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358869 (3-(1-Benzofuran-2-yl)-N-[(2S)-1-hydroxy-3-methylbu...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358860 (N-[3-(dimethylamino)propyl]-3-[4-(morpholin-4-yl)f...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358868 (3-(1-Benzofuran-2-yl)-N-[2-(dimethylamino)ethyl]im...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358856 (N-(2-methoxyethyl)-N-methyl-3-[4-(morpholin-4-yl)f...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358858 (N-[(2R)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358861 (3-(1-Benzofuran-2-yl)-N-[3-(dimethylamino)propyl]i...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358853 (N-(3-methoxypropyl)-3-[4-(morpholin-4-yl)furo[3,2-...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358862 (3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxypropan-2-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.10 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358852 (N-benzyl-3-[4-(morpholin-4-yl)furo[3,2-c]pyridin-2...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358860 (N-[3-(dimethylamino)propyl]-3-[4-(morpholin-4-yl)f...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358857 (N-(2-methoxyethyl)-3-[4-(morpholin-4-yl)furo[3,2-c...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358863 (3-(1-Benzofuran-2-yl)-N-(3-methoxypropyl)imidazo[1...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358865 (3-(1-Benzofuran-2-yl)-N-benzylimidazo[1,2-b]pyrida...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358852 (N-benzyl-3-[4-(morpholin-4-yl)furo[3,2-c]pyridin-2...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358858 (N-[(2R)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358864 (3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxy-3-methylbu...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358853 (N-(3-methoxypropyl)-3-[4-(morpholin-4-yl)furo[3,2-...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358859 (N-[(2S)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358861 (3-(1-Benzofuran-2-yl)-N-[3-(dimethylamino)propyl]i...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358866 (3-(1-Benzofuran-2-yl)-N-(2-methoxyethyl)imidazo[1,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358856 (N-(2-methoxyethyl)-N-methyl-3-[4-(morpholin-4-yl)f...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358867 (3-(1-Benzofuran-2-yl)-N-benzyl-N-methylimidazo[1,2...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358862 (3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxypropan-2-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358863 (3-(1-Benzofuran-2-yl)-N-(3-methoxypropyl)imidazo[1...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 9.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358865 (3-(1-Benzofuran-2-yl)-N-benzylimidazo[1,2-b]pyrida...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358864 (3-(1-Benzofuran-2-yl)-N-[(2R)-1-hydroxy-3-methylbu...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358857 (N-(2-methoxyethyl)-3-[4-(morpholin-4-yl)furo[3,2-c...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 12 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358866 (3-(1-Benzofuran-2-yl)-N-(2-methoxyethyl)imidazo[1,...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358859 (N-[(2S)-1-hydroxypropan-2-yl]-3-[4-(morpholin-4-yl...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 21 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358867 (3-(1-Benzofuran-2-yl)-N-benzyl-N-methylimidazo[1,2...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 23 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358868 (3-(1-Benzofuran-2-yl)-N-[2-(dimethylamino)ethyl]im...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 34 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358869 (3-(1-Benzofuran-2-yl)-N-[(2S)-1-hydroxy-3-methylbu...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 42 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358854 (N-[2-(dimethylamino)ethyl]-N-methyl-3-[4-(morpholi...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 88 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358855 ((4-Methylpiperazin-1-yl){3-[4-(morpholin-4-yl)furo...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 110 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity of compounds of the present invention was quantified employing the MKNK1 TR-FRET assay as described in the following paragr... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358854 (N-[2-(dimethylamino)ethyl]-N-methyl-3-[4-(morpholi...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 140 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| MAP Kinase interacting Kinase (Homo sapiens (Human)) | BDBM358855 ((4-Methylpiperazin-1-yl){3-[4-(morpholin-4-yl)furo...) | PDB GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 280 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET... | US Patent US10214545 (2019) BindingDB Entry DOI: 10.7270/Q2833V9N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
